This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Matthew Anderson, CEO of Vanguard Scientific, offered insights on the challenges cannabis ingredient suppliers and buyers face from seed to sale during Cannabis Products Exchange, held virtually July 30-31.
Willow Biosciences Inc. says it has successfully developed a scalable process for producing cannabigerol (CBG) with greater than 99 percent purity, no detectable THC and demonstrated production at 500-litre scale.
Company has completed numerous pilot-scale fermentations.
September 4, 2020
Demetrix Inc., a biotechnology company that makes safe and effective cannabinoids, has commenced 15,000-liter demo-scale fermentation production of the rare cannabinoid cannabigerol (CBG).
Research is underway to help determine the potential of cannabis in the realm of pain management. This is particularly important work in light of the ongoing opioid crisis in America.
Mile High Labs supplies Ocean Spray’s CarryOn sparkling waters.
August 10, 2020
Mile High Labs has closed a Series B equity financing round from American entrepreneur John Paul DeJoria. The financing will be used to pay off existing debt and accelerate the development of its manufacturing and formulations platform.
In order to help bring the benefits of CBD and other non-psychoactive cannabinoids to a wider, national audience unencumbered by federal restriction, the industry needs to provide data assuring the ingredients’ safety.